Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-Current Deffered Revenue: 2009-2022

Historic Non-Current Deffered Revenue for Cytokinetics (CYTK) over the last 6 years, with Mar 2022 value amounting to $87.0 million.

  • Cytokinetics' Non-Current Deffered Revenue changed negligibly% to $87.0 million in Q1 2022 from the same period last year, while for Mar 2022 it was $87.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $87.0 million for FY2021, which is negligibly% changed negligibly from last year.
  • Cytokinetics' Non-Current Deffered Revenue amounted to $87.0 million in Q1 2022, which was down 0.00% from $87.0 million recorded in Q4 2021.
  • Cytokinetics' Non-Current Deffered Revenue's 5-year high stood at $87.0 million during Q4 2020, with a 5-year trough of $87.0 million in Q4 2020.
  • In the last 3 years, Cytokinetics' Non-Current Deffered Revenue had a median value of $87.0 million in 2022 and averaged $87.0 million.